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Looking at the pathological stage, there was a negative effect of adju-
vant chemotherapy for stage Ia. The risk reduction was 8% for stage Ib, 
17% for stages II and III.
The effect of chemotherapy did not vary according to age, gender, PS, 
type of surgery and histology.
When the drug combined with cisplatin was analyzed, the risk reduc-
tion was 20% for Vinorelbine, 7% for other biotherapies and 2% for 
tritherapies.
In the 1888 patients who received the combination of vinorelbine and 
cisplatin, the 5-year absolute beneﬁt was 9% and the hazard ratio was 
0.95 (0.76-1.20) for stage I vs 0.68 (0.56-0.83) and 0.62 (0.50-0.76) for 
stage II and III respectively. 
In conclusion, the results of the recently reported large randomized 
studies of adjuvant chemotherapy suggest a 5 to 15% improvement of 
survival at 5 years.The LACE pooled analysis of the new generation of 
trials has included over 4,000 patients. It conﬁrms the role of adjuvant 
chemotherapy in resected NSCLC except for stage Ia patients. It sug-
gests the use of vinorelbine in combination with cisplatin. The results 
of the IALT-Bio program suggest to evaluate the expression of ERCC1 
in order to determine which patients are more likely to beneﬁt from 
chemotherapy. If these results are conﬁrmed, we will enter the era of 
tailored therapy for resected NSCLC. 
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Several prospective randomized trials for patients with early stage 
NSCLC (stages I-IIIA) have conﬁrmed a survival beneﬁt with 
cisplatin-based adjuvant chemotherapy, as demonstrated in the 1995 
meta-analysis performed by the NSCLC Collaborative Group. On the 
other hand, uracil-tegafur was also shown to improve survival among 
patients with stage I adenocarcinoma in Japan.
Japan Lung Cancer Research Group trial: Attending physicians 
of this group randomly assigned patients with completely resected 
pathological stage I adenocarcinoma of the lung to receive either oral 
uracil-tegafur (250 mg of tegafur per square meter of body-surface area 
per day) for two years or no treatment. Randomization was performed 
with stratiﬁcation according to the pathological tumor category (T1 
vs. T2), sex, and age. From January 1994 through March 1997, 999 
patients were enrolled. Twenty patients were found to be ineligible and 
were excluded from the analysis after randomization; 491 patients were 
assigned to receive uracil-tegafur and 488 were assigned to observa-
tion. The median duration of follow-up for surviving patients was 73 
months. The difference in overall survival between the two groups was 
statistically signiﬁcant in favor of the uracil-tegafur group (P=0.04 by a 
stratiﬁed log-rank test). Grade 3 toxic effects occurred in 10 of the 482 
patients (2 percent) who actually received uracil-tegafur. This trial has 
demonstrated adjuvant therapy with uracil-tegaful (UFT) afforded an 
improvement of 4% in the 5-year survival rate and a relative risk reduc-
tion of 26% in mortality at 5 years among patients with T1-2N0 (stage 
I) disease. In particular, an improvement in the 5-year survival rate of 
11%, favoring chemotherapy with UFT has been reported in the subset 
of patients with T2N0 (stage IB) disease.
Meta-analysis of six UFT trials: Among nine trials of postoperative 
adjuvant UFT-containing chemotherapy, six trials comparing surgery 
alone with surgery plus UFT were identiﬁed. Of six trials, two were 
three-arm trials including cisplatin-based chemotherapy followed by 
UFT, and data from that arm were not included in the meta-analysis. Of 
2,003 eligible patients, most (98.8%) had squamous cell carcinoma or 
adenocarcinoma, and most had stage I disease; the tumor classiﬁcation 
was T1 in 1,308 (65.3%), T2 in 674 (33.6%), and the nodal status was 
N0 in 1,923 (96.0%). The two treatment groups did not differ signiﬁ-
cantly in major prognostic factors. The median duration of follow-up 
was 6.44 years. The survival rates at 5 and 7 years were signiﬁcantly 
higher in the surgery plus UFT group (81.5% and 76.5%, respectively) 
than in the surgery alone group (77.2% and 69.5%, respectively; P = 
.011 and .001, respectively). The overall pooled hazard ratio was 0.74, 
and its 95% CI was 0.61 to 0.88 (P = .001). This meta-analysis showed 
that postoperative adjuvant chemotherapy with UFT was associated 
with improved 5- and 7-year survival in a Japanese patient population 
composed primarily of stage I adenocarcinoma patients. Another meta-
analyses based on abstracts have estimated a relative risk reduction in 
mortality of 11-13% at 5 years.
